What insurance policy changes affect code G99.0?

There are 4 tracked policy changes affecting code G99.0, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G99.0?

Payers that have issued tracked updates for code G99.0 include: Aetna.

How do I get notified when code G99.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G99.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G99.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

G99.0 Insurance Policy Changes

ICD-10 G99.0 is officially defined as "Autonomic neuropathy in diseases classified elsewhere." code G99.0 is referenced in 4 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G99.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 19, 2026Medium impact
Vitamin B-12 Therapy (CPB 0536, reviewed 2025-08-21)
Aetna covers intramuscular or subcutaneous vitamin B-12 injections as medically necessary only for members with current or previously documented B-12 deficiency and one of the listed diagnoses, including pernicious anemia, malabsorption syndromes, gastrectomy or small intestine surgery, certain neuropathies, dementia secondary to B-12 deficiency, metformin-related deficiency, methotrexate or pralatrexate use, and pemetrexed (Alimta) use. Aetna considers vitamin B-12 injections for all other indications experimental, investigational or unproven, including autism, depression, fibromyalgia, migraine prophylaxis, and weight loss. Homocysteine measurement is medically necessary in persons with borderline vitamin B-12 deficiency when the results will impact the member's management, while holotranscobalamin measurement for diagnosing B-12 deficiency is listed as unproven.
Aetna · Identified Aug 18, 2026Medium impact
Holter Monitors (CPB 0019, reviewed 2026-03-13)
Aetna considers Holter monitoring medically necessary for diagnostic evaluation of adult members with listed conditions, including palpitations, syncope or near syncope, unexplained dizziness, and possible or documented long QT syndrome, and for asymptomatic congenital complete atrioventricular block in pediatric patients. Holter monitoring is considered experimental, investigational, or unproven for all other indications because its effectiveness for those indications has not been established. CPT codes 93224, 93225, 93226 and 93227 are covered if the selection criteria are met.
Aetna · Identified Aug 13, 2026Medium impact
Pedobarography (CPB 0294, reviewed 2026-04-17)
Aetna considers pedobarography (foot pressure studies) experimental, investigational, or unproven, because the medical literature does not contain reliable evidence that it improves diagnosis and management of foot conditions or health outcomes. CPT 96001, comprehensive computer-based motion analysis with dynamic plantar pressure measurements during walking, is listed as not covered for the indications in this policy. Related CPT codes include motion analysis, surface electromyography and physician interpretation, related HCPCS codes include ankle-foot orthoses and orthopedic shoes, and ICD-10 codes for diabetes with neurological complications, pressure ulcers of the ankle and heel, and osteoarthritis of the ankle and foot are listed as not covered for these indications.
Aetna · Identified Aug 18, 2026Low impact
Thermal Perfusion Probe for Monitoring Regional Cerebral Blood Flow (CPB 0703, reviewed 2025-11-24)
This is a historical copy of Aetna's clinical policy on thermal perfusion probes for monitoring regional cerebral blood flow (CPB 0703), last reviewed November 24, 2025 and first found by PolicyChanges in August 2026. Aetna treats the probe as experimental, investigational or unproven for acute neurological conditions, and the source gives no effective date.

Watch G99.0

Get one email when a payer policy names G99.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Vitamin B-12 Therapy (CPB 0536, reviewed 2025-08-21)

Holter Monitors (CPB 0019, reviewed 2026-03-13)

Pedobarography (CPB 0294, reviewed 2026-04-17)

Thermal Perfusion Probe for Monitoring Regional Cerebral Blood Flow (CPB 0703, reviewed 2025-11-24)

What insurance policy changes affect code G99.0?

Which payers have updated policy for code G99.0?

How do I get notified when code G99.0 policy changes?

Why do payers change policies for code G99.0?